Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(9 months ago) | |
US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(2 years from now) | |
US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(4 years from now) | |
US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(3 months ago) | |
US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(2 years from now) | |
US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(2 years from now) | |
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(2 years from now) | |
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(3 years from now) | |
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(3 years from now) | |
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(4 years from now) | |
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(8 years from now) |
Tasigna is owned by Novartis.
Tasigna contains Nilotinib Hydrochloride.
Tasigna has a total of 14 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tasigna are:
Tasigna was authorised for market use on 22 March, 2018.
Tasigna is available in capsule;oral dosage forms.
Tasigna can be used as treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml), treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation, a method for the treatment of leukemias.
Drug patent challenges can be filed against Tasigna from 23 March, 2028.
The generics of Tasigna are possible to be released after 07 October, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Mar 23, 2029 |
Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
New Dosing Schedule(D-170) | Dec 22, 2020 |
New Patient Population(NPP) | Mar 22, 2021 |
New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
New Indication(I-627) | Jun 17, 2014 |
Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); A method for the treatment of leukemias; Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml...
Dosage: CAPSULE;ORAL